Pathologic handling and reporting of prostate tissue specimens in patientsreceiving neoadjuvant hormonal therapy: Report of the Pathology Committee

Prior meetings of the International Conference on Neoadjuvant Hormonal Ther apy in Prostate Cancer identified areas of concern in the pathologic analys is of post-treatment specimens. In response, a pathology subcommittee was f ormed to address the questions that had been raised. Recommendations are ma de here concerning pretreatment biopsy review and reporting, handling and r eporting of radical prostatectomy specimens, Gleason scoring of treated can cer, grading of therapy effect, role of immunohistochemistry procedures, an d the significance of high-grade prostatic intraepithelial neoplasia. Neoad juvant trials with both surgery and radiation therapy were considered in dr awing up these recommendations.